Strengthening Safeguards for Psychiatric Uses of Ketamine
Brian S. Barnett, Roger D Weiss, Gerard Sanacora
JAMA Psychiatry February 12, 2025 DOI: 10.1001/jamapsychiatry.2024.4787 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Ketamine Esketamine |
| Keywords | Medline Law |
| Citations | 7 |
| Key findings | Ketamine use in psychiatry requires optimized safety protocols, including patient selection and monitoring, to mitigate risks. |
Abstract
This Viewpoint discusses challenges related to ketamine use within psychiatry and offers recommendations for optimizing patient safety.
Comparable studies
Other narrative reviews on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms | 2018 | Review | |
| Mechanisms of Ketamine Action as an Antidepressant | 2018 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) | 2013 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement |
Citations in the library
Cited by 5
- Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression JAMA Psychiatry October 22, 2025
- Synaptic priming: A framework for pharmacotherapy in depression. Neuron November 19, 2025
- Urological symptoms following ketamine treatment for psychiatric disorders: A systematic review. Journal of Psychopharmacology June 30, 2025
- Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search. Fundamental and Clinical Pharmacology July 1, 2026
- Psychedelics: Future Therapeutics in Major Depression? Advances in experimental medicine and biology 2026
Cites 4
- Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. New England Journal of Medicine May 24, 2023
- Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review BJPsych Open December 23, 2021
- Long-Term Safety and Maintenance of Response With Esketamine Nasal Spray in Participants With Treatment-Resistant Depression: Interim Results of the SUSTAIN-3 Study Neuropsychopharmacology May 12, 2023
- Formulary Coverage of Esketamine and Ketamine for Depression in Ohio Health Insurance Marketplace and Medicaid Plans. Journal of Psychiatric Practice March 1, 2024